We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An investigational oral drug lowered lipoprotein(a) ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that ...

Please provide your email address to receive an email when new articles are posted on . Muvalaplin, the first oral therapy developed to lower lipoprotein(a), did so in a phase 1 study. An extended ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all ...

SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced ...

Pfizer (PFE) and BioNTech (BNTX) announced topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-microgram dose of the ...